Watson Pharmaceuticals Invests in $15M New Jersey Expansion
"Over the past year, we have outgrown our current administrative headquarters site, as our U.S. and global business has rapidly grown," said Paul Biscaro, Watson president and CEO. "This new facility will ensure that we have a single location for the leadership and shared services functions that are driving our global growth."
New Jersey's Business Employment Incentive Program (BEIP) has extended Watson a grant of approximately $7.3 million over the next 10 years from the state's Economic Development Authority. It has also been approved for a $290,000 Business Retention and Relocation Assistance Grant (BRRAG) to retain 200 jobs in New Jersey.
Watson was the country's third largest producer of generic drugs in 2009 based on prescriptions dispensed. It specializes in drugs for urology and women's health.
Sweden-based Volvo Construction Equipment Adds Shippensburg, Pennsylvania, Training Complex
“Made in America” Executive Order to Affect International Companies and FDI
Trends in Office and Industrial Parks
34th Annual Corporate Survey & the 16th Annual Consultants Survey
Another Look at Rural Economies
2020 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts
Supply Chain Execs Respond as Pandemic Creates E-Commerce Surge